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Abstract:  
 
Background: Grade 3 ischemia (G3I) in the 12-lead electrocardiogram (ECG) predicts poor outcome 
in patients with ST-elevation myocardial infarction (STEMI). The outcome of G3I in “real-life” patient 
cohorts is unclear. 
Methods: The aim of the study was to establish the prognostic significance of grade 2 ischemia (G2I), 
G3I and the STEMI patients excluded from ischemia grading (No grade of ischemia, NG) in a real-life 
patient population. We assessed in-hospital, 30-day and 1-year mortality as well as other endpoints. 
Results: The NG patients had more comorbidities and longer treatment delays than the two other 
groups. Short-term and 1-year mortality were highest in patients with NG and lowest in patients with 
G2I. Maximum troponin level was highest in G3I, followed by NG and G2I. In logistic regression 
multivariable analysis, NG was independently associated with 1-year mortality. 
Conclusions: NG predicted poor outcome in STEMI patients. G2I predicted relatively favorable 
outcome.  
 
Keywords: ST-elevation myocardial infarction; myocardial ischemia; grade of ischemia; 
electrocardiography; prognosis; mortality. 
 
 
 
 
 
 
Introduction 
 
In ST-elevation myocardial infarction (STEMI), the electrocardiogram (ECG) provides crucial 
diagnostic and prognostic information especially in the acute phase of the disease process. Grade 3 
ischemia (G3I), as defined by the Sclarovsky-Birnbaum grading system[1, 2], has been confirmed as a 
strong predictor of poor outcome and lower probability of ST-segment resolution in patients treated 
with either fibrinolytic therapy (FT) [3, 4] or primary percutaneous coronary intervention (pPCI) [4, 
5]. Patients with G3I have larger infarcts [6, 7], more microvascular damage [8] and a higher 
thrombus burden [9] than patients with Grade 2 ischemia (G2I). There is also more rapid progression 
of myocardial necrosis over time and less myocardial salvage in patients with G3I [10]. Evolution or 
persistence of G3I from the pre-hospital to the pre-PCI ECG predicts larger infarct size and less 
myocardial salvage compared to patients with persisting G2I or with decreasing grade from G3I to 
G2I [7]. Furthermore, G3I predicts reduced left ventricular regional wall motion [11], lower ejection 
fraction and more left ventricular remodeling in STEMI patients treated with PCI [12]. 
 
The differences in the underlying pathophysiological mechanisms of the different grades of ischemia 
(GI) have not been well established. The original hypothesis by Sclarovsky and Birnbaum, indicating 
differences in myocardial protection by subtotal occlusion, collateral flow or myocardial 
preconditioning, have been supported by previous studies, which showed a more rapid progression 
of myocardial necrosis in G3I [10]. 
 
Per definition, patients with T-wave inversions, ventricular rhythm, left or right bundle branch block 
or other ventricular conduction defects are excluded from the ischemia grading [2], but there is no 
study data on the outcome of these patients. Previously, it has been shown that a broad QRS in 
STEMI predicts adverse outcome [13]. T-wave inversions also predicted higher mortality in STEMI – 
at least in late-presenting patients [14]. 
 Although many studies have established the importance of the grade of ischemia classification in the 
risk assessment of patients with STEMI, it remains unclear whether this is the case in “real-life” 
STEMI populations without specific exclusion criteria.  
 
The aim of the present study was to evaluate the prognostic role of the GI in a STEMI population 
with only ECG-related exclusion criteria and to study the outcome of patients excluded from 
ischemia grading.  
 
 
Material and methods 
 
Study population 
 
This study comprised two Finnish non-randomized STEMI studies. The STEMI 2005 study was 
conducted in the region of the Tampere University Hospital with a population of ≈1.2M. Data on the 
incidence, demographics, treatment strategies and delays were collected for consecutive STEMI 
patients (n=310) in four hospital districts during a six-month period [15]. Regarding reperfusion 
therapy, both pPCI and FT were used. The study was observational and treatment choices were 
based on prevailing international and regional guidelines. 
 
In the HUS-STEMI study, patients (n=448) were included during one year (2007-2008) in the district 
of the Helsinki University Hospital with a population of ≈1.6M [16]. The choice of reperfusion therapy 
- FT or pPCI - was based on the decision by the consulting cardiologist. FT was recommended for 
hemodynamically stable patients when the time from symptom onset to treatment was ≤ 3 hours.  
As in the STEMI 2005 study, use of ancillary anti-thrombotic therapy was based on prevailing 
guidelines and the study was observational.   
 
The distribution of “No grade” (NG = patients excluded from ischemia grading based on ECG 
findings), G2I and G3I was 20%, 69% and 10% in the STEMI 2005 study, and 19%, 67% and 14%, 
respectively in the HUS-STEMI study (p value for the differences 0.319). 
 
There were no pre-specified exclusion criteria in the two studies. The inclusion criteria were as 
follows: 
Acute chest pain/discomfort and 
1) ST-elevations of ≥ 0,2 mV in at least 2 of the leads V1-3 and/or  
2) ST-elevations of ≥ 0,1 mV in at least 2 other contiguous leads (V4-6; I, aVL; II, III, aVF) or  
3) new or presumably new left bundle branch block 
 
The local Ethics Committees approved the study protocol. A written informed consent was signed by 
the patients before enrollment.  
 
Renal insufficiency was defined as creatinine >150 μmol/l (1.70 mg/dl) on admission. We used 
troponin T for the maximum troponin level with a cut-off <0.01 μg/l. 
 
For the present study, mortality data were collected from the official national registry (Statistics 
Finland) and regarding in-hospital and 1-year mortality, no patients were lost for follow-up. 
Regarding other endpoints, data from the two studies were used. Data were not available for 33/679 
(5 %) patients at 30-day follow-up. 
 
The patients were divided into three groups according to the revascularization strategy: FT with or 
without rescue-PCI, pPCI and “No reperfusion therapy” (NRT). The latter was defined as no FT or PCI 
within 4 hours from presentation. 
 
The primary endpoint was mortality at one year. Other pre-specified endpoints were in-hospital 
mortality, 30-day mortality and 30-day MACE (major adverse cardiovascular events, a composite of 
cardiovascular death, stroke, re-infarction and new, unplanned revascularization procedures). 
 
 
ECG analysis 
 
The ECG data were analyzed by one of the investigators (KK), who at the time of analysis was blinded 
to the clinical data. In borderline cases (n=100), a consensus was sought together with 2-3 senior 
cardiologists (ME, KN and YB). Patients with missing/incomplete (n=25), or non-interpretable ECG-
recordings (n=12) were excluded. Although included in the two studies by the investigators on-site, 
we found that the ST-elevations did not fulfill the inclusion criteria in 46/758 (6%) patients. These 
patients were excluded. A total of 675/758 (89%) patients were included in the final study group: 
278/310 (90%) from the STEMI 2005 and 397/448 (89%) from the HUS-STEMI study. For ischemia 
grading, all other standard leads than aVR were used.  
 
Pathological Q waves were defined according to the Third Universal Definition of Myocardial 
Infarction [17] and patients with pathological Q waves were included in the GI analysis. Pathological 
Q waves outside the leads with maximal ST elevation were ignored.  
 
G3I was defined as distortion of the terminal portion of the QRS complex in at least two adjacent 
leads. In an rS type complex, typically in leads V1-V3, elevation of the S wave to or above the base 
line was defined as G3I (Fig. 1). In a qR type complex, typically in all the other leads, elevation of the J 
point  ≥50% of the height of the R wave was considered as G3I (Fig. 2). In the presence of left axis 
deviation (≤ -30°) and S waves in V5-V6, disappearance of the S wave in V4 was interpreted as G3I 
[2]. The ECG was graded according to the most severe ischemia regardless of the infarct localization. 
For example, patients with anterior (anterolateral) STEMI were classified as G3I if they had G3I in the 
lateral leads I and aVL.  
 
There were 131 patients in whom it was not possible to define the grade of ischemia. These patients 
formed the NG group in the present study (Fig.3). The NG group consisted of patients with any T-
wave inversion ≥0.05 mV in the leads with the maximum ST elevation and QRS duration ≤120 ms 
(n=79) and patients with a QRS complex wider than 120 ms (n=52), including 15 right bundle branch 
block, 13 left bundle branch block, 18 non-specific intraventricular conduction delay, 4 
atrioventricular dissociation with ventricular rhythm, 1 accelerated idioventricular rhythm and 1 
ventricular paced rhythm. 
 
 
Statistical analysis 
 
The data were analyzed with SPSS Statistics 22. We compared NG, G2I and G3I with respect to 
different pre-specified variables. In all categorical variables, we used the χ² test or Fisher´s exact test. 
Because the distribution of all continuous variables was skewed, we used median values and used 
the Mann-Whitney U test or Kruskal-Wallis test for the difference between the groups. Interquartile 
ranges were defined using the weighted average.   
 
We performed a logistic regression univariate analysis for the grades of ischemia using one-year 
mortality as the endpoint. We present odds ratios (OR) with 95% confidence intervals (CI). The 
variables with a p-value <0.1 were chosen for the multivariable analysis. In case of missing data, valid 
percentages are reported. 
    
    
Results 
 
G2I was found in 67.9% (n=458), G3I in 12.7% (n=86) and NG in 19.4% (n=131) (Fig. 4). The baseline 
characteristics are shown in Table 1. Patients in the NG group more often had prior congestive heart 
failure than G2I or G3I (12.4%, 5.2% and 1.2%, respectively, p=0.001) patients. The rate of prior CABG 
was 10.7%, 2.6% and 1.2% in the respective groups (p<0.001). Killip class >1 was found in 46.6%, 
26.1% and 32.9%, respectively (p<0.001). The patients with NG were more often on angiotensin 
convertase inhibitor (ACE) inhibitor or angiotensin receptor blocker medication (34.6%) as compared 
to G21 (23.9%) and G3I (22.4%), patients (p=0.036). The rate of pPCI in the NG, G2I and G3I groups 
was 42.7%, 33.6% and 29.1%, respectively (p=0.075). Patients in the NG group were less often 
treated with FT (32.1%, 56.8% and 62.8%; p<0.001) and had the highest rate of no acute reperfusion 
therapy (25.2%, 9.6% and 8.1%; p<0.001).  
 
The NG group had the longest median delay from symptom onset to ECG (172 minutes, quartiles 69-
380) as compared to the G2I (80 min, quartiles 41-172) and G3I (75 min, quartiles 42-182) groups. P 
value for the difference was <0.001.  The median delay from symptom onset to treatment was 286 
min (quartiles 144-556), 150 min (quartiles 91-248) and 110 min (quartiles 72-215), p<0.001, 
respectively. We found no significant differences between the groups regarding rate of current 
smoking, diabetes, hyperlipidemia, hypertension, prior STEMI, prior angina pectoris, prior transient 
ischemic attack or stroke, renal insufficiency, prior PCI or prior medication (except for ACE inhibitor 
and angiotensin receptor blocker). Also the differences in age and gender were non-significant.  
 Outcome of patients with respect to the GI is shown in Table 2. Patients with NG had the highest 30-
day mortality (15,6%) followed by G3I (14.8%) and G2I (6.8%). P-value for the difference was 0.003. 
30-day cardiovascular (CV) mortality was 14.8%, 12.3% and 6.4% in the respective groups (p=0.007). 
30-day MACE occurred in 23.0% of the patients with NG, 22.2% of G3I and 13.4% of G2I (p=0.013). 
Patients with NG had the highest and those with G2I the lowest in-hospital (p<0.001) and 1-year 
(p<0.001) mortality. The maximum troponin T level was highest in the G3I group and lowest in the 
G2I group. 
 
In the Kaplan-Meier curve (Fig. 5), G2I stands out as the ECG marker with the best outcome early on; 
G3I and NG have similar high early mortality. After the first 90 days, the decline in survival is steeper 
in NG than in G3I. P-value for the difference between the three groups is <0.001. 
 
Table 3 shows the results of logistic regression univariate and multivariable analyses. In the 
univariate analysis, G3I (OR 2.00, 95% CI 1.07-3.72, p=0.029) and NG (OR 2.95, 95% CI 1.79-4.84, 
p<0.001) were associated with increased 1-year mortality as compared to G2I. In the multivariable 
analysis, G3I (OR 2.36, 95% CI 0.924-6.03, p=0.073) had a tendency towards and NG (OR 2.82, 95% CI 
1.36-5.85, p=0.005) was associated with increased 1-year mortality. Other variables significantly 
associated with increased 1-year mortality in the multivariable analysis were age and Killip class >1. 
 
 
Discussion 
 
In our all-comers study, in-hospital, 30-day and 1-year mortality was more than twice as high in G3I 
as in G2I. Our results align with previous studies, which, contrary to the present study, almost 
without exception included non-ECG related exclusion criteria, such as limits for time from symptom 
onset, age, previous MI, and excess bleeding risk. In the DANAMI-2 trial, where both FT and pPCI 
were used, 30-day mortality for G3I and G2I was 9.7% vs. 4.8%, respectively [4]. Also in another large 
study (n=2.603), almost the double in-hospital mortality was found in G3I compared with G2I [18]. In 
the Thrombolysis in Myocardial Infarction 4 trial, mortality was even three times higher in patients 
with G3I than in those with G2I [6].  
 
Previous studies on grades of ischemia have clearly demonstrated the adverse outcome of G3I but 
they may have excluded a wide range of potentially high-risk STEMI patients. Our all-comers study 
confirmed the relatively benign course of G2I, but also identified a clearly high-risk group, namely 
STEMI patients, for whom ischemia grading does not apply. The patients with NG showed the highest 
mortality in short-term and mid-term follow-up. This patient group has not been well established in 
the literature. In the DANAMI-2 study, the patients excluded from ischemia grading had 12.6% 30-
day mortality, as compared to 9.7% in G3I and 4.8% in G2I. Within the 253 excluded patients, 
however, there were 48 patients with missing ECG, 11 with incomplete ECG and 11 with no ST 
elevation. [4] Thus the excluded patients were not directly comparable with the NG group of the 
present study.  
 
The NG group in the present study comprised patients with T-wave inversions or a broad QRS 
complex. Patients with NG more often had prior congestive heart failure than G2I or G3I. This is 
understandable, because bundle branch block or other intraventricular conduction defect is often 
seen in heart failure [19]. In acute STEMI, QRS duration is known to affect outcome [13]. In patients 
with coronary artery disease, a wider QRS is associated with sudden cardiac arrest [20]. NG patients 
also more often had a history of prior CABG compared with the other groups, evidently reflecting 
more severe coronary disease. Longer delays from symptom onset to ECG and to treatment logically 
lead to later stages of the infarct process, which can be expressed as T-wave inversion in the 
presenting ECG – the most frequent ECG pattern in the NG group. These patients may have less 
potential for saving ischemic myocardium from injury with reperfusion therapy [21]. T-wave 
inversions in the baseline ECG in STEMI predict high mortality at least in late-presenting patients [14, 
22]. NG is probably not a uniform patient group but a cluster of ECG patterns associated with poor 
outcome. It is plausible that NG represents either a later stage of the infarct process with less 
potential to save myocardium by reperfusion therapy or an infarct in a structurally abnormal heart. 
 
Of the three groups in this study, the patients with G3I seemed to have the largest infarcts as 
reflected by the highest maximum troponin level. Despite lower maximum troponin levels, NG 
patients had similar poor early outcome in the Kaplan-Meier analysis (Figure 5). Perhaps a smaller 
infarct in a structurally altered heart results in as poor outcome as a larger infarct in a previously 
healthy heart. Survival analysis also shows that mortality in G2I and G3I remains low after the first 90 
days, whereas mortality in NG is higher. This may reflect the higher mortality of patients with heart 
failure independent of the STEMI. 
 
Both G3I and NG were associated with increased 1-year mortality as compared to G2I in the logistic 
regression univariate analysis. In NG, the association was more distinct. In the multivariable analysis, 
NG was independently associated with increased 1-year mortality, as compared to G2I. In G3I, there 
was a tendency towards association with increased 1-year mortality (p=0.073). Our study indicates 
that G2I can be used as a reliable predictor of relatively favorable outcome in STEMI. On the other 
hand, NG reliably predicts poor outcome. G3I patients have high in-hospital, 30-day and 1-year 
mortality as compared to G2I, but in real life G2I and NG may be better prognostic indicators than 
G3I. Interestingly, in another real life study, Zalenski et al [23] found no significant association 
between G3I and 2-year mortality. Their study population did not comprise STEMI patients 
exclusively and the number of included patients was quite low (n=229).  
 
Although no firm conclusions can be drawn from the present study about the exact reasons for poor 
outcome in the NG patients, it is possible that the effect of therapeutic measures is more limited in 
these patients than in those with G2I and G3I. 
The present study is the first one to report the incidence of G2I and G3I in a STEMI population 
without (non-ECG) exclusion criteria. The rate of G3I proved to be lower than in most previous 
studies, where the proportion usually has been between 20% and 50% [4, 7, 18]. We have no 
definite explanation for the low number of patients with G3I in our study. The previous publications 
usually represent either retrospective analysis of randomized trials of FT or pPCI, or single center 
studies of consecutive patients. There was wide variation in the exclusion and inclusion criteria 
between the studies. Due to the potential bleeding risks with FT, randomized trials with these agents 
had the most exclusion criteria. One could speculate that mostly G2I patients were excluded. 
The definition of the GI may explain some of the differences in the relative proportions of G2I and 
G3I. Like in our study, most investigators excluded patients with inverted T waves, but investigators 
have used different definitions for T-wave inversion. In our study, only T-wave inversion in the 
lead(s) with maximal ST elevation resulted in exclusion, while in some studies, any T-wave inversion 
in a lead with ST-segment elevation resulted in study exclusion [18]. Most previous authors define 
G3I as absence of an S wave below the isoelectric line in leads V1-V3 (leads that usually have a 
terminal S wave) or a J-point amplitude ≥50% of the R-wave amplitude in all other leads. This 
definition was also used in the present study. However, other definitions exist; Lee et al [24] 
interpreted leads V1-V3 as qR type in the presence of Q waves and absence of S-waves. According to 
our definition, leads V1-V3 are by default rS type and disappearance of S-waves in those leads should 
always be interpreted as G3I in anterior wall STEMI. Garcia-Rubira et al [25] only used the criterion of 
J-point/R-wave ratio >0.5 in all leads for QRS distortion, ignoring the disappearance of S waves in V1-
V3. They did not mention excluding ECGs with T wave inversion either [25]. 
Conclusion 
In our all-comers study, STEMI patients not eligible for ischemia grading due to broad QRS or 
inverted T waves, proved to have higher mortality than those without these ECG characteristics.  We 
also found that G2I on the presenting ECG results in survival benefit regarding short- and mid-term 
mortality in comparison with other STEMIs. The present study implies that STEMI is a group of 
different diseases instead of one uniform disease. In the future it would be interesting to study 
whether these groups benefit from different treatment strategies. 
Limitations 
There are some limitations to be reported in our study. The study population consists of two sub-
studies with differences in reperfusion therapy. However, the distribution of GIs was similar in the 
two studies. As the distribution is similar, the study results are relevant for the whole study 
population. 
At the time of the studies, troponin T was the most widely used biochemical marker of myocardial 
injury. In some hospitals, troponin I was used and, hence, 52 patients had to be excluded from the 
troponin analyses 
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Table 1. Baseline characteristics based on ECG ischemia grading (NG = no grade). Location of the 
STEMI and pathologic Q waves were not determined in patients with NG.  
NG n=135 G2I n=458 G3I n=86 
% n % n % n p value 
Male  62.6 82 64.4 295 74.4 64 0.154 
Current smoker 29.4 35 37.1 161 36.3 29 0.297 
Diabetes 25.2 33 17.1 78 18.6 16 0.108 
Hyperlipidaemia 40.5 53 47.4 217 39.5 34 0.204 
Hypertension 56.9 74 56.3 258 47.7 41 0.307 
Prior STEMI 16.3 21 9.9 45 8.2 7 0.082 
Prior angina 31.1 37 27.6 121 28.4 23 0.750 
Prior CHF 12.4 16 5.2 24 1.2 1 0.001 
Prior TIA/stroke 11.5 15 7.2 33 7.0 6 0.268 
Renal insufficiency 6.9 9 2.4 11 3.5 3 0.045 
Prior PCI 9.2 12 5.5 25 7.0 6 0.301 
Prior CABG 10.7 14 2.6 12 1.2 1 <0.001 
Killip class >1 46.6 61 26.1 119 32.9 28 <0.001 
Pathological Q-waves 20.3 93 38.4 33 
STEMI in anterior 
location 
45.6 209 46.5 40 
ASA 36.2 47 28.4 130 23.5 20 0.105 
Clopidogrel 3.1 4 0.9 4 1.2 1 0.153 
Warfarin 6.2 8 5.2 24 3.5 3 0.686 
β blocker 38.5 50 31.9 146 24.1 20 0.088 
Calcium channel 
blocker 
20.0 26 16.6 76 12.9 11 0.392 
Statin 24.8 32 19.9 91 16.3 14 0.283 
ACEi/ARB 34.6 45 23.9 109 22.4 19 0.036 
pPCI 42.7 56 33.6 154 29.1 25 0.075 
FT 32.1 42 56.8 260 62.8 54 <0.001 
NRT 25.2 33 9.6 44 8.1 7 <0.001 
NG G2I G3I 
Median Quartiles Median 
Quartil
es 
Median Quartiles p value 
Age (years) 
69.5 58.9-78.6 65.5 
56.7-
76.0 
66.8 55.3-76.8 0.267 
Time from symptom 
onset to ECG 
(minutes) 
172 69.0-380 80.0 
41.0-
172 
75.0 42.3-182 <0.001 
Time from symptom 
onset to treatment 
(minutes) 
286 144-556 150 
91.0-
248 
110 72.0-215 <0.001 
STEMI = ST elevation myocardial infarction, CHF = congestive heart failure, TIA = transient ischemic 
attack, PCI = percutaneous coronary intervention, pPCI = primary PCI, CABG = Coronary artery bypass 
graft, ACEi = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, pPCI = 
primary PCI, FT = fibrinolytic therapy, NRT = No reperfusion therapy within 4 hours from 
presentation 
Table 2. Outcome based on the grade of ischemia. 
NG G2I G3I 
P value 
% n % n % n 
30-day follow-up 122 439 81 
mortality 15.6 19 6.8 30 14.8 12 0.003 
CV mortality 14.8 18 6.4 28 12.3 10 0.007 
AMI 6.6 8 4.6 20 6.2 5 0.610 
stroke 0.8 1 1.6 7 3.7 3 0.284 
new non-elective 
CABG/PCI 
2.5 3 3.0 13 2.5 2 0.939 
MACE  23.0 28 13.4 59 22.2 18 0.013 
Lost for follow-up 9 19 5 
Mortality 131 458 86 
In-hospital  16.0 21 5.2 24 11.6 10 <0.001 
1-year  25.2 33 10.3 47 18.6 16 <0.001 
NG 
Median Quartiles 
Grade 2 
Median Quartiles 
Grade 3 
Median Quartiles 
p value 
Maximum 
troponin 
2.72 1.00-5.38 1.87 0.463-5.15 3.93 1.02-8.22 0.001 
CV = cardiovascular, AMI = acute myocardial infarction, CABG = coronary artery bypass grafting, PCI = 
percutaneous coronary intervention, MACE = major adverse cardiovascular endpoints 
Table 3. Logistic regression univariate and multivariable analyses with 1-year mortality as the 
endpoint. 
Univariate analysis Multivariable analysis 
OR 95% CI p value OR 95% CI p value 
Grade of ischemia 
G2I Ref. Ref. 
G3I 2.00 1.07-3.72 0.029 2.36 0.924-6.03 0.073 
No grade 2.95 1.79-4.84 <0.001 2.82 1.36-5.85 0.005 
Male 0.450 0.291-0.697 <0.001 1.26 0.632-2.50 0.514 
Age 1.09 1.07-1.11 <0.001 1.05 1.02-1.09 0.002 
Current smoker 0.489 0.269-0.890 0.019 1.31 0.584-2.95 0.511 
Diabetes 2.63 1.63-4.25 <0.001 1.82 0.854-3.88 0.121 
Hyperlipidaemia 0.595 0.379-0.935 0.024 0.579 0.286-1.17 0.129 
Hypertension 1.94 1.22-3.08 0.005 1.50 0.620-3.62 0.369 
Prior STEMI 1.24 0.639-2.40 0.527 
Prior angina 2.00 1.21-3.28 0.007 1.69 0.885-3.23 0.112 
Prior CHF 5.64 2.91-10.9 <0.001 1.45 0.455-4.62 0.529 
Prior TIA/stroke 3.15 1.69-5.87 <0.001 1.79 0.663-4.82 0.251 
Renal insufficiency 8.91 3.79-21.0 <0.001 1.40 0.325-6.02 0.653 
Prior PCI 1.41 0.635-3.15 0.397 
Prior CABG 1.39 0.514-3.77 0.516 
Killip class >1 9.71 5.89-16.0 <0.001 5.83 2.91-11.7 <0.001 
Time from symptom 
onset to ECG  
1.00 1.00-1.00 0.443 
Time from symptom 
onset to treatment 
1.00 1.00-1.00 0.826 
Pathological Q-waves 1.82 1.14-2.90 0.013 1.65 0.812-3.34 0.167 
STEMI in anterior 
location 
1.27 0.825-1.96 0.278 
Reperfusion therapy 
NRT Ref. Ref. 
FT 0.341 0.195-0.599 <0.001 1.05 0.397-2.75 0.929 
pPCI 0.294 0.158-0.546 <0.001 0.980 0.369-2.60 0.968 
ASA 2.16 1.39-3.37 0.001 1.15 0.534-2.47 0.722 
Clopidogrel 3.11 0.765-12.7 0.113 
Warfarin 2.23 1.01-4.91 0.048 0.881 0.226-3.44 0.855 
β blocker 3.04 1.95-4.75 <0.001 1.36 0.645-2.87 0.419 
Calcium channel blocker 2.47 1.50-4.06 <0.001 1.69 0.761-3.75 0.197 
Statin 1.21 0.722-2.04 0.465 
ACEi/ARB 1.63 1.02-2.60 0.042 0.635 0.293-1.37 0.248 
For abbreviations, see Table 2. 
Fig. 1. Grade 2 ischemia (Panel A) and grade 3 ischemia (Panel B) in anterior STEMI 
(50 mm/s). In an rS type complex (typically V1–V3), G3I is shown as rising of S-wave 
above baseline.
Fig. 2. Grade 2 ischemia (Panel A) and Grade 3 ischemia (Panel B) in inferior STEMI (50 
mm/s). In a qR type complex, G3I is shown as ST-elevation >50% of the height of the R-
wave.
Fig. 3. An example of a patient in the “No grade” group. Anterior STEMI with QRS  > 120 ms 
due to right bundle branch block (50 mm/s). 
   
 
